Literature DB >> 19302554

Cytochrome P450 metabolites of arachidonic acid play a role in the enhanced cardiac dysfunction in diabetic rats following ischaemic reperfusion injury.

M H M Yousif1, I F Benter, R J Roman.   

Abstract

1 This study examined the contribution of cytochrome P450 metabolites of arachidonic acid in mediating ischaemia/reperfusion (I/R)-induced cardiac dysfunction in normal and diabetic rats. 2 We first compared the metabolism of arachidonic acid in microsomes prepared from the hearts of control rats and rats treated with streptozotocin (55 mg kg(-1)) to induce diabetes. The production of dihydroxyeicosatrienoic acids and epoxyeicosatrienoic acids (EETs) were similar in microsomes prepared from the hearts of control and diabetic rats, but the production of 20-hydroxyeicosatetraenoic acid (20-HETE) was two-fold higher in diabetic hearts than in control animals. 3 We then compared the change in left ventricular pressure (P(max)), left ventricular end-diastolic pressure, coronary flow and coronary vascular resistance in isolated perfused hearts obtained from control and diabetic animals after 40 min of global ischaemia (I) followed by 30 min of reperfusion (R). The decline in cardiac function was three- to five-fold greater in the hearts obtained from diabetic vs. control animals. 4 Pretreatment of the hearts with N-hydroxy-N'-(4-butyl-2-methyl-phenyl)-formamidine (HET0016, 1 microm), a selective inhibitor of the synthesis of 20-HETE, for 30 min before I/R resulted in significant improvement in the recovery of cardiac function in the hearts obtained from diabetic but not in control rats. Perfusion with an inhibitor of soluble epoxide hydrolase, 1-cyclohexyl-3-dodecyl urea (CDU), before I/R improved the recovery of cardiac function in hearts obtained from both control and diabetic animals. Perfusion with both HET0016 and CDU resulted in significantly better recovery of cardiac function of diabetic hearts following I/R than that seen using either drug alone. Pretreatment of the hearts with glibenclamide (1 microm), an inhibitor of ATP-sensitive potassium channels, attenuated the cardioprotective effects of both CDU and HET0016. 5 This is the first study to suggest that acute blockade of the formation of 20-HETE and/or reduced inactivation of EETs could be an important strategy to reduce cardiac dysfunction following I/R events in diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302554      PMCID: PMC2831291          DOI: 10.1111/j.1474-8673.2009.00429.x

Source DB:  PubMed          Journal:  Auton Autacoid Pharmacol        ISSN: 1474-8665


  33 in total

1.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

2.  Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway.

Authors:  Kasem Nithipatikom; Eric R Gross; Michael P Endsley; Jeannine M Moore; Marilyn A Isbell; John R Falck; William B Campbell; Garrett J Gross
Journal:  Circ Res       Date:  2004-09-23       Impact factor: 17.367

3.  Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation.

Authors:  Benjamin B Davis; David A Thompson; Laura L Howard; Christophe Morisseau; Bruce D Hammock; Robert H Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

4.  Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.

Authors:  John D Imig; Xueying Zhao; Jorge H Capdevila; Christophe Morisseau; Bruce D Hammock
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

Review 5.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

6.  Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway.

Authors:  John Seubert; Baichun Yang; J Alyce Bradbury; Joan Graves; Laura M Degraff; Scott Gabel; Rebecca Gooch; Julie Foley; John Newman; Lan Mao; Howard A Rockman; Bruce D Hammock; Elizabeth Murphy; Darryl C Zeldin
Journal:  Circ Res       Date:  2004-07-15       Impact factor: 17.367

7.  Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.

Authors:  Xueying Zhao; Tatsuo Yamamoto; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock; Janet Stewart; Jennifer S Pollock; David M Pollock; John D Imig
Journal:  J Am Soc Nephrol       Date:  2004-05       Impact factor: 10.121

8.  Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes.

Authors:  N Shimojo; T Ishizaki; S Imaoka; Y Funae; S Fujii; K Okuda
Journal:  Biochem Pharmacol       Date:  1993-08-17       Impact factor: 5.858

Review 9.  Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.

Authors:  Arthur A Spector; Xiang Fang; Gary D Snyder; Neal L Weintraub
Journal:  Prog Lipid Res       Date:  2004-01       Impact factor: 16.195

10.  Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model.

Authors:  S N Batchu; E Law; D R Brocks; J R Falck; J M Seubert
Journal:  J Mol Cell Cardiol       Date:  2008-10-10       Impact factor: 5.000

View more
  15 in total

Review 1.  The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.

Authors:  Xizhen Xu; Rui Li; Guangzhi Chen; Samantha L Hoopes; Darryl C Zeldin; Dao Wen Wang
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

2.  1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Authors:  Tristan E Rose; Christophe Morisseau; Jun-Yan Liu; Bora Inceoglu; Paul D Jones; James R Sanborn; Bruce D Hammock
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

3.  Elevated level of pro-inflammatory eicosanoids and EPC dysfunction in diabetic patients with cardiac ischemia.

Authors:  Yossi Issan; Edith Hochhauser; Austin Guo; Katherine H Gotlinger; Ran Kornowski; Dorit Leshem-Lev; Eli Lev; Eyal Porat; Eitan Snir; Carl I Thompson; Nader G Abraham; Michal Laniado-Schwartzman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-01-03       Impact factor: 3.072

4.  20-Hydroxyeicosatetraenoic acid induces apoptosis in neonatal rat cardiomyocytes through mitochondrial-dependent pathways.

Authors:  Yuyan Bao; Xueying Wang; Wei Li; Dan Huo; Xin Shen; Yong Han; Jiang Tan; Qinghua Zeng; Chengwen Sun
Journal:  J Cardiovasc Pharmacol       Date:  2011-03       Impact factor: 3.105

Review 5.  20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension.

Authors:  Jan M Williams; Sydney Murphy; Marilyn Burke; Richard J Roman
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

Review 6.  Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.

Authors:  Fan Fan; Ying Ge; Wenshan Lv; Matthew R Elliott; Yoshikazu Muroya; Takashi Hirata; George W Booz; Richard J Roman
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

7.  Peripheral soluble epoxide hydrolase inhibition reduces hypernociception and inflammation in albumin-induced arthritis in temporomandibular joint of rats.

Authors:  Juliana Maia Teixeira; Henrique Ballassini Abdalla; Rosanna Tarkany Basting; Bruce D Hammock; Marcelo Henrique Napimoga; Juliana Trindade Clemente-Napimoga
Journal:  Int Immunopharmacol       Date:  2020-07-28       Impact factor: 4.932

8.  Pretreatment with low-dose gadolinium chloride attenuates myocardial ischemia/reperfusion injury in rats.

Authors:  Min Chen; Yuan-yuan Zheng; Yun-tao Song; Jing-yi Xue; Zheng-yang Liang; Xin-xin Yan; Da-li Luo
Journal:  Acta Pharmacol Sin       Date:  2016-03-07       Impact factor: 6.150

Review 9.  20-HETE in the regulation of vascular and cardiac function.

Authors:  Petra Rocic; Michal Laniado Schwartzman
Journal:  Pharmacol Ther       Date:  2018-07-23       Impact factor: 12.310

10.  Determination of the dominant arachidonic acid cytochrome p450 monooxygenases in rat heart, lung, kidney, and liver: protein expression and metabolite kinetics.

Authors:  Ahmed A El-Sherbeni; Mona E Aboutabl; Beshay N M Zordoky; Anwar Anwar-Mohamed; Ayman O S El-Kadi
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.